Regulatory Mechanisms of Activator Protein-1 in Cancer Pathophysiology

Activator Protein-1 (AP-1) is a dimeric transcription factor formed by members of the Jun, Fos, Maf and ATF families. It integrates a variety of extracellular signals via mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K) and NF-κB pathways to modulate gene networks governing proliferation, differentiation, apoptosis, motility and inflammation. In cancer, aberrant upstream signalling leads to altered AP-1 composition, post-translational modifications and subcellular localisation, resulting in dysregulated expression of target genes that drive tumour initiation, progression, metastasis and therapy resistance. Jun–Fos heterodimers typically promote cell cycle entry through induction of cyclin D1 and repression of cell cycle inhibitors, while Fos–Fos or Jun–Jun homodimers may exert context-specific effects on apoptosis and stress responses. Phosphorylation by ERK, JNK and p38 MAPKs enhances AP-1 DNA-binding and transcriptional activity, whereas ubiquitin-mediated degradation provides feedback control. Interactions with co-activators, chromatin remodelers and non-coding RNAs further refine the specificity of AP-1 in diverse tumour types. Crosstalk between AP-1 and epithelial-to-mesenchymal transition (EMT) programmes underlies metastatic dissemination and the emergence of drug-tolerant persister cells. Emerging evidence also implicates cytoplasmic pools of Fos proteins in phospholipid synthesis to support membrane biogenesis in rapidly dividing cancer cells. A detailed understanding of these regulatory layers is critical for the design of therapies that selectively disrupt oncogenic AP-1 functions while preserving its roles in normal tissue homeostasis.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Regulatory Mechanisms of Activator Protein-1 in Cancer Pathophysiology publication trend

The graph below shows the total number of articles in regulatory mechanisms of activator protein-1 in cancer pathophysiology across all publications each year (not limited to Nature Index journals).

Technical terms

Activator Protein-1 (AP-1): A dimeric transcription factor complex formed by Jun, Fos, Maf or ATF family proteins that regulates gene expression in response to diverse signals.

Post-translational modification: Covalent chemical changes to a protein (e.g. phosphorylation, ubiquitination) that influence its stability, localisation or activity.

Epithelial-to-Mesenchymal Transition (EMT): A cellular programme in which epithelial cells acquire mesenchymal traits, enhancing motility and invasiveness during development and cancer metastasis.

Dimerisation: Association of two protein subunits, as in Jun–Fos heterodimers, which is essential for DNA binding and transcriptional control.

Tumour microenvironment: The local cellular milieu of a tumour, including stromal cells, immune cells, extracellular matrix and signalling molecules that influence cancer progression.

References

1. Role of Fra-2 in cancer. Cell Death & Differentiation (2023).
2. The potential of activator protein 1 (AP-1) in cancer targeted therapy. Frontiers in Immunology (2023).
3. FRA-1 as a Regulator of EMT and Metastasis in Breast Cancer. International Journal of Molecular Sciences (2023).